| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
18:0 LYSO-PE targets the lysophosphatidic acid receptor 1 (LPA1). By binding to LPA1, it induces a transient increase in intracellular calcium concentration ([Ca²⁺]i) in certain cell types. This effect is specific to certain cell lines, such as SK-OV3 and PC-12 cells, and is not observed in MDA-MB-231 cells. The compound's role as a lysophospholipid makes it a valuable tool for studying LPA1 signaling and calcium mobilization.
|
|---|---|
| ln Vitro |
18:0 LYSO-PE is a medicine that can elicit an increase in [Ca2+]i in SK-OV3 cells and PC-12 cells, but not in MDA-MB-231 cells [1].
In vitro, 18:0 LYSO-PE induces a transient increase in [Ca²⁺]i in PC12 rat neuronal cells in a concentration-dependent manner. This effect can be blocked by the LPA1 receptor antagonist AM095. It is used as a standard in lipid analysis by mass spectrometry. These properties make it a valuable tool for studying lipid signaling and calcium homeostasis. |
| ln Vivo |
In vivo, 18:0 LYSO-PE is not used as a therapeutic agent. Its primary application is as a research tool and analytical standard.
|
| Enzyme Assay |
In vitro non-cell assays for 18:0 LYSO-PE are primarily analytical, such as ESI-MS/MS, where it is used as a standard for lipid analysis.
|
| Cell Assay |
In vitro cell-based assays for 18:0 LYSO-PE involve measuring changes in intracellular calcium concentration in cell lines such as SK-OV3, PC-12, and MDA-MB-231. Cells are loaded with a calcium-sensitive dye, and the fluorescence signal is measured in response to the compound. The specificity of the response can be confirmed using LPA1 receptor antagonists.
|
| Animal Protocol |
In vivo animal studies are not typically performed with 18:0 LYSO-PE, as it is a research reagent and not a therapeutic agent.
|
| ADME/Pharmacokinetics |
18:0 LYSO-PE has a molecular weight of 481.60 g/mol and a molecular formula of C₂₃H₄₈NO₇P. It should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for 6 months. It is a lysophospholipid.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 18:0 LYSO-PE is not extensively detailed. As a lysophospholipid, it can have biological effects at high concentrations. It is not intended for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
The 1-stearoyl-sn-glycerol-3-phosphate ethanolamine zwitterion is obtained by transferring a proton to the phosphate group of 1-stearoyl-sn-glycerol-3-phosphate ethanolamine. It is both the lysophosphatidylethanolamine zwitterion 18:0 and the 1-acyl-sn-glycerol-3-phosphate ethanolamine zwitterion. It is a tautomer of 1-stearoyl-sn-glycerol-3-phosphate ethanolamine. PE (18:0/0:0) is a metabolite found or produced in Saccharomyces cerevisiae.
18:0 LYSO-PE is a lysophospholipid that induces an increase in intracellular calcium via LPA1 receptor. It is used as a standard for lipid analysis by mass spectrometry. It is not approved for clinical use and is intended for research purposes only. |
| Molecular Formula |
C23H48NO7P
|
|---|---|
| Molecular Weight |
481.603488922119
|
| Exact Mass |
481.316
|
| CAS # |
69747-55-3
|
| PubChem CID |
46891690
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.812
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
32
|
| Complexity |
471
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[NH3+])O
|
| InChi Key |
BBYWOYAFBUOUFP-JOCHJYFZSA-N
|
| InChi Code |
InChI=1S/C23H48NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(26)29-20-22(25)21-31-32(27,28)30-19-18-24/h22,25H,2-21,24H2,1H3,(H,27,28)/t22-/m1/s1
|
| Chemical Name |
2-azaniumylethyl [(2R)-2-hydroxy-3-octadecanoyloxypropyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~2 mg/mL (~4.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0764 mL | 10.3821 mL | 20.7641 mL | |
| 5 mM | 0.4153 mL | 2.0764 mL | 4.1528 mL | |
| 10 mM | 0.2076 mL | 1.0382 mL | 2.0764 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
